Edward A. Pesicka
Known title: DirectorCIK: 0001439487
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 10, 2026
Accendra Health Receives NYSE Continued Listing Notice. Accendra Health received a notice from the NYSE regarding continued listing standards, with the company stating its intent to cure the deficiency. This regulatory development adds pressure to a stock that is already trading near its 52-week low. Additionally, Bank of America disclosed a 10.8% stake in the company as of September 30.
Transaction History
| FTRE | ▲ Buy | Option Exercise | 38,817 | $0 | 6/10/2026 | View on chart |
| ACH | ▼ Sell | Tax Withholding | 17,692 | $54K | 5/15/2026 | View on chart |
| ACH | ▼ Sell | Tax Withholding | 58,945 | $120K | 3/20/2026 | View on chart |
| ACH | ▼ Sell | Tax Withholding | 35,208 | $246K | 5/15/2025 | View on chart |
| FTRE | ▲ Buy | Option Exercise | 7,282 | $0 | 5/14/2025 | View on chart |
| ACH | ▼ Sell | Tax Withholding | 14,715 | $148K | 3/20/2025 | View on chart |
| ACH | ▲ Buy | Grant | 445,279 | $0 | 3/3/2025 | View on chart |
| FTRE | ▲ Buy | Option Exercise | 6,354 | $0 | 7/18/2024 | View on chart |
| ACH | ▼ Sell | Tax Withholding | 45,604 | $902K | 5/15/2024 | View on chart |
| ACH | ▼ Sell | Tax Withholding | 58,126 | $1.5M | 3/15/2024 | View on chart |
| ACH | ▲ Buy | Grant | 148,134 | $0 | 3/1/2024 | View on chart |
| ACH | ▲ Buy | Grant | 366 | $6K | 12/29/2023 | View on chart |
| ACH | ▲ Buy | Grant | 923 | $15K | 6/30/2023 | View on chart |
| ACH | ▼ Sell | Open Market | 27,488 | $530K | 6/16/2023 | View on chart |
| ACH | ▼ Sell | Open Market | 5,837 | $113K | 6/16/2023 | View on chart |
| ACH | ▼ Sell | Open Market | 5,455 | $105K | 6/16/2023 | View on chart |
| ACH | ▼ Sell | Open Market | 5,455 | $105K | 6/15/2023 | View on chart |
| ACH | ▼ Sell | Open Market | 27,488 | $529K | 6/15/2023 | View on chart |
| ACH | ▼ Sell | Open Market | 5,837 | $112K | 6/15/2023 | View on chart |
| ACH | ▼ Sell | Open Market | 118,928 | $2.5M | 6/9/2023 | View on chart |
| ACH | ▼ Sell | Open Market | 118,928 | $2.5M | 6/8/2023 | View on chart |
| ACH | ▼ Sell | Open Market | 118,927 | $2.6M | 6/7/2023 | View on chart |
| ACH | ▼ Sell | Open Market | 118,927 | $2.5M | 6/6/2023 | View on chart |
| ACH | ▼ Sell | Tax Withholding | 18,555 | $348K | 5/15/2023 | View on chart |
| ACH | ▼ Sell | Tax Withholding | 45,163 | $831K | 5/11/2023 | View on chart |
| ACH | ▼ Sell | Tax Withholding | 265,362 | $3.5M | 3/15/2023 | View on chart |
| ACH | ▲ Buy | Grant | 128,882 | $0 | 3/1/2023 | View on chart |
| ACH | ▲ Buy | Grant | 178,109 | $0 | 3/1/2023 | View on chart |
| ACH | ▲ Buy | Grant | 32 | $529 | 12/30/2022 | View on chart |
| ACH | ▲ Buy | Grant | 551 | $15K | 6/30/2022 | View on chart |
| ACH | ▼ Sell | Open Market | 12,028 | $432K | 5/17/2022 | View on chart |
| ACH | ▼ Sell | Open Market | 75,675 | $2.7M | 5/16/2022 | View on chart |
| ACH | ▼ Sell | Open Market | 53,875 | $1.9M | 5/16/2022 | View on chart |
| ACH | ▼ Sell | Open Market | 1,100 | $40K | 5/16/2022 | View on chart |
| ACH | ▼ Sell | Tax Withholding | 9,881 | $356K | 5/16/2022 | View on chart |
| ACH | ▼ Sell | Open Market | 1,914 | $69K | 5/16/2022 | View on chart |
| ACH | ▼ Sell | Tax Withholding | 45,163 | $1.7M | 5/11/2022 | View on chart |
| ACH | ▼ Sell | Tax Withholding | 63,740 | $2.7M | 3/7/2022 | View on chart |
| ACH | ▼ Sell | Tax Withholding | 382,784 | $16.4M | 3/4/2022 | View on chart |
| ACH | ▲ Buy | Grant | 58,453 | $0 | 3/3/2022 | View on chart |
| ACH | ▲ Buy | Grant | 606,898 | $0 | 2/9/2022 | View on chart |
| ACH | ▼ Sell | Open Market | 3,598 | $145K | 11/3/2021 | View on chart |
| ACH | ▼ Sell | Open Market | 23,728 | $988K | 11/3/2021 | View on chart |
| ACH | ▼ Sell | Open Market | 29,315 | $1.2M | 11/3/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 13, 2026
Barclays Upgrades Fortrea, Boosts Target to $23
Barclays has upgraded Fortrea Holdings to overweight and lifted its target price to $23. The upgrade follows a recent rise in the stock price and a mention of the company as an overrated pick in a Yahoo article. Analysts still see upside potential, with the average target of $21.04 and a 52‑week range that includes the new level. The stock’s high‑beta rating indicates it may continue to move sharply with market swings.
Barclays Upgrades Fortrea, Boosts Target to $23. Barclays has upgraded Fortrea Holdings to overweight and lifted its target price to $23. The upgrade follows a recent rise in the stock price and a mention of the company as an overrated pick in a Yahoo article. Analysts still see upside potential, with the average target of $21.04 and a 52‑week range that includes the new level. The stock’s high‑beta rating indicates it may continue to move sharply with market swings.